Lung Cancer Clinical Trial

Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®

Summary

This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subject signed inform consent
Suspected or proven non-small cell lung cancer (NSCLC) in the upper lobes of the left or right lung
Pre-operative criteria
Lung nodule suspicious for NSCLC
Mass ≤ 7 cm in maximum diameter by CT scan of the chest and upper abdomen
Clinical stage I or Clinical stage II
Not pregnant or nursing
Negative pregnancy test in premenopausal women
Fertile patients must use effective contraception
More than 5 years since prior invasive malignancy unless non melanoma skin cancer or in-situ cancer

Exclusion Criteria:

-

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

40

Study ID:

NCT03290534

Recruitment Status:

Recruiting

Sponsor:

CivaTech Oncology

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

NYU Langone Health
New York New York, 10016, United States More Info
Mohamed El Zaeedi
Contact
Michael Zervos, MD
Principal Investigator
Benjamin Cooper, MD
Sub-Investigator

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

40

Study ID:

NCT03290534

Recruitment Status:

Recruiting

Sponsor:


CivaTech Oncology

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.